CS MEDICA A/S Reports Third Quarter Results, Showing Highest Gross Profit and Lowest Operating Loss

CS MEDICA A/S announced its financial results for the third quarter of the 2025/2026 financial year, covering April to June 2026. The company reported a significant increase in revenue and a substantial improvement in profitability compared to the previous periods.

During the third quarter, revenue reached DKK 2.9 million, a notable increase from DKK 0.3 million in the second quarter. Gross profit rose to DKK 1.7 million, up from DKK 0.6 million in the same quarter last year, resulting in a gross margin of 60 percent. The company attributed this performance to the successful progression of previously delayed orders into production and invoicing, including a significant white-label delivery to a European partner.

The operating result (EBIT) for the quarter was a loss of DKK 0.4 million. While still a loss, this represents the lowest operating loss recorded by the company so far in the current financial year. This improvement is linked to both the increased revenue and the company's reduced cost base.

CS MEDICA A/S continues to focus on its core business within the health sector. The company's strategy involves strengthening its market position through product development and expanding its distribution networks internationally. Further financial updates are expected following the close of the next reporting period.